An endogenous sodium pump inhibitor has been purified from human plasma. The purification scheme involved large scale dialysis, extraction of lyophilized dialysate by methanol followed by preparative and semipreparative scale reverse-phase high-performance chromatography. A single peak of biologically active material was obtained enriched by a factor of greater than 10 billion. This material showed high chromatographic polarity, was inactivated by charring, strong acid, or alkali, and was resistant to short-term boiling. The purified material had a molecular weight between 300 and 900 g/mol and was insensitive to type I esterase and a variety of proteolytic enzymes. The purified factor inhibited the ouabain-sensitive uptake of ^Rb by human erythrocytes, binding of [ 3 H]ouabain, and activity of dog kidney Na,K-adenosine triphosphatase (ATPase) with high affinity (<0.3 nM) in a time-and dose-dependent manner. Maximally effective concentrations of the digitalislike factor showed no effect on either human red blood cell Mg-or Ca-ATPase, rabbit muscle sarcoplasmic reticulum Ca-ATPase, or guinea pig stomach H,K-ATPase. The purified material is a highly potent selective inhibitor of the ion transport, receptor, and hydrolytic functions of the sodium pump. The characteristic properties of this substance suggest it may be a mammalian endogenous digitalis and may be similar to the sodium transport inhibitor detected in the plasma of volume-sensitive forms of experimental and human hypertension. (Hypertension 1989;13:681-689)
T he maintenance of transmembrane gradients for sodium and potassium ions plays a fundamental role in the function of excitable and nonexcitable cells. The generation and maintenance of these gradients is the direct consequence of the activity of the plasma membrane sodium pump. An unknown humoral factor that inhibits the sodium pump has been suggested to play an important role as a natriuretic or vasoconstrictive agent in volume regulation and the etiology of low-renin forms of experimental and human hypertension. 1 -4 By virtue of its inhibitory action on the sodium pump, this agent may also be the long-sought mammalian counterpart to the cardenolides, here termed endogenous digitalislike factor (EDLF). Despite many attempts, little progress has been made in the purification and identification of EDLF. At least three interrelated reasons account for this situation. First, a highly enriched tissue source for the plasma EDLF has not been identified. Second, in view of the small quantity of EDLF present in plasma or urine, several hundred liters of these fluids are required to generate sufficient high-grade material for structural analyses. Third, during the development of purification procedures, the choice of the screening assays for EDLF is of critical importance because of the co-presence of various interferences, 5 -7 some of which may appear as false positives.
In this study, EDLF has been purified from the plasma obtained from mildly volume-expanded individuals. Plasma was chosen as a source material because a sodium pump inhibitor of physiological and pathophysiological interest has been routinely detected in this fluid. 8 - 16 Moreover, the purified material has been characterized and shown to fulfill some of the criteria for consideration as an endogenous mammalian counterpart to the cardenolides.
Materials and Methods

Sample Specifications
Human plasma (125 1) was obtained by routine plasmapheresis of 30 donors (age range 25-75 years), irrespective of sex or blood pressure status. Some individuals were being treated for Guillain-Barre syndrome or polyneuropathy. Preliminary studies had shown that EDLF was present in all donors regardless of their clinical status. Four of the donors had borderline essential hypertension. No individuals had received cardiotonic steroids, and the majority had taken no other medication. Typically, 2.5-3.6 1 plasma were exchanged in each individual over a 2-hour period and replaced with a saline solution containing mildly hyperoncotic human serum albumin to induce a mild expansion of intravascular volume. The plasma was stored at -20° C or -70° C until use (1-8 weeks).
Dialysis
Before chromatography, the excess plasma protein was removed by dialysis at 23° C for 24 hours using cellulose acetate membranes (Spectrapor, Spectrum Medical Industries, Los Angeles, California) against 2.4 volumes of a solution containing 10 mM NH 4 Ac, pH 6.8. The exclusion limit was a molecular weight of 6,000-8,000. The dialysate was lyophilized, and the solids were extracted with 0.1 volumes methanol. The methanol soluble fraction obtained by centrifugation was subjected to flash evaporation. Residual water and methanol were removed by lyophilization. The dried extract was reconstituted in water for chromatography.
Chromatography
A Waters Prep 500 high-performance chromatography system (Waters Associates, Danvers, Massachusetts) was used to chromatograph individual batches equivalent to 15.4 1 plasma (step 1). Samples were applied to a 5.7x30-cm column packed with 15-20 jum Vydac octadecylsilane (Separations Group, Hesperia, California) and preequilibrated with water containing 0.1% trifluoroacetic acid. After washing, bound materials were eluted at a flow rate of 50 ml/min with a linear gradient of CH 3 CN containing trifluoroacetic acid, and 100-ml fractions were collected. Fractions were dried and reconstituted in water for assay. An area of interest was identified, and batches equivalent to 5 1 plasma were rechromatographed (step 2) on an Altex 1 x 25-cm C18 column (Beckman Instruments, Fullerton, California), preequilibrated as before, and run at a flow of 5 ml/min. Active materials were eluted by a linear 50-minute gradient, and the area of interest was rechromatographed (step 3) in 10-liter plasmaequivalent batches on the same column preequilibrated with water containing 0.1% heptafluorobutyric acid. Active materials were eluted by a biphasic gradient program of isopropanol containing heptafluorobutyric acid at 3 ml/min. The active fraction was rechromatographed (step 4) on the same column and eluted using CH 3 CN containing trifluoracetic acid as before. The active fraction was further purified in batches of 31 1 plasma equivalents on a 0.8x30-cm Waters Phenyl column (step 5) eluted at 3 ml/min with a biphasic gradient program of CH 3 CN containing 50 mM tetraethylammonium formate. The active fraction was further enriched (step 6) by rechromatography in the same system using a biphasic gradient program of isopropanol containing heptafluorobutyric acid.
Sodium Pump Activity
Activity was determined using modifications to methods described elsewhere. 8 For assay of chromatographic fractions, the assay volume was 150 /u. 1 and contained (mM): NaCl 150, RbCl 2 with tracer amounts of ^Rb (New England Nuclear, Boston, Massachusetts), MgSO 4 1, CaCl 2 2, glucose 5, and HEPES-Tris 20, pH 7.4. In characterization studies, the assay volume was 310 /A and contained (mM): NaCl 120, RbCl 2 with trace ^Rb, MgCl 2 2, NaH 2 PO 4 1, glucose 5, and HEPES-Tris 10, pH 7.4. All incubations were initiated by addition of washed red blood cells (final hematocrit 16%) and, after 2 hours at 37° C, were quenched at appropriate intervals with ice-cold medium lacking 86 Rb. The 86 Rb associated with the red blood cell pellet was determined by gamma counting. 8 The ouabain-sensitive uptake was determined from total uptake minus uptake in the presence of a maximal dose of ouabain (1 mM). A value of l.llxlO 13 cells/1 was used to convert all flux data to nmol Rb uptake/10 8 cells. In some experiments, samples were preincubated with red blood cells at 37° C in the absence of all extracellular Rb. After this, small aliquots of RbCl containing 86 Rb were added to initiate transport, and the uptake was followed for 1 additional hour.
Sodium-Potassium Adenosine Triphosphatase Activity
Na,K-ATPase was purified from the outer medulla of dog kidney by standard methods. 17 Activity was determined at 37° C from rate measurements in 1 ml final volume of the coupled optical assay 14 containing (in mM or as labeled): KC120, NaCl 100, MgSO 4 4.5, EGTA 5, ATP-Na 2 3, phosphoenolpyruvate-tricyclohexylammonium 1.2, NADH 0.3, TES-Tris 100, pH 7.4,5 units lactate dehydrogenase, and 5 units pyruvate kinase. The maximal rate of the coupled system was greater than 500 times the corresponding rate of the Na,K-ATPase under all conditions. Enzyme protein was determined by dye binding 18 with dried bovine serum albumin as standard. In some experiments as indicated in the figure legends, samples were preincubated with the Na,K-ATPase in the absence of K + for 2 hours at 37° C to achieve maximal inhibition before rate determination. 
Preparation of Other Adenosine Triphosphatases
Ca-ATPase was purified from longitudinal sarcoplasmic reticulum as described. 19 Activity was determined in the coupled optical assay described before with the following modifications: 150 mM KC1, 0.5 mM EGTA, 0.51 mM CaCl 2 , 1 mM ouabain, and all NaCl omitted. Ca-ATPase was taken as the difference in enzyme activity before and after addition of 2 mM EGTA to the reaction.
Human red blood cell ghosts were prepared as described. 20 Na,K-ATPase was determined as described above, Mg-ATPase was defined as activity that remained in the presence of 1 mM ouabain, and Ca-ATPase was measured as noted for the sarcoplasmic reticulum enzyme. H,K-ATPase was isolated from guinea pig stomach. Activity was defined as ouabain-insensitive K + -and valinomycinstimulated ATPase.
Results
Chromatography
The results from the preparative scale reversephase chromatography of the methanol extract of the dialysate corresponding to 15 1 plasma are shown in Figure 1A . A series of peaks with strong ultraviolet (UV) absorption at 220 nm were initially eluted before the acetonitrile gradient. Although a series of inhibitory materials were detected at various elution times, many of these showed little evidence of a digitalislike mechanism of action, that is, time-dependent binding in a manner sensitive to extracellular potassium ions (KJ. The material eluting between 85 and 100 minutes was inhibitory in a time-and K o -dependent manner in the sodium pump assay.
Results of the second step of chromatography of this material are shown in Figure IB . A single major peak of inhibitory activity was recovered at 17-18 minutes. The inhibitory material from the second step was rechromatographed in the third step ( Figure  1C ) with an isopropanol/heptafluorobutyric acid solvent system to explore possible differences in column selectivity for the inhibitory activity and the associated UV contaminants. In the presence of this ion pairing agent, the inhibitory activity eluted between 19.5 and 20 minutes and preceded the majority of UV absorbing contaminants. A large fraction of the residual UV absorbance that remained associated with the inhibitory material was removed in the fourth step by rechromatography in acetonitrile/trifluoroacetic acid as shown in Figure ID . A single inhibitory peak, associated with a small number of UV absorbing peaks, was obtained at 32 minutes. In the fifth step of purification ( Figure IE) , this material was further enriched by switching from a C18 to a phenyl column and using an acetonitrile/tetraethylammonium formate solvent system. Inhibitory activity was recovered at 30 minutes. The nature of the solvent system precluded the routine use of 220 nm as a monitoring wavelength in this case. Therefore, the inhibitory material was associated with a small UV peak at 280 nm, a less sensitive wavelength. In the sixth and final step shown in Figure IF , this material was purified to apparent homogeneity by means of a phenyl column and isopropanol/heptafluorobutyric acid solvent system. A major peak of inhibitory activity coeluted with a single peak of UV absorbing material at 220 nm. Based on a dry weight for 125 1 human plasma (10.375 kg), the apparent purification factor of the purified material (~0.8 fjug) was 7.7x 10". This figure is not corrected for recovery of EDLF over the last five steps of chromatography. This may be estimated from a comparison of the relation between inhibition of ^Rb uptake and the number of plasma equivalents in the first ( Figure  1A ) and last chromatographic steps ( Figure IF) . This comparison suggests that the yield of EDLF was roughly 10% of that initially present in the methanolic extract of the dialysate. This adjustment reduces the overall purification factor to approximately 7.7xlO 10 . These values, given the uncertainty of the molecular weight for EDLF and the native plasma concentration, are close to theoretical homogeneity.
Size-exclusion high-performance chromatography with Waters Ultrastyragel (Waters Associates) indicated that EDLF migrated between molecular weight markers corresponding to 300 and 900 g/mol (not shown). EDLF appeared in the void volume of a number of weak cation and anion exchange highperformance columns (not shown). These results suggest that EDLF is primarily uncharged.
Characterization of Endogenous Digitalislike Factor
Preincubation of a variety of proteolytic (trypsin, prolidase, chymotrypsin) and hydrolytic enzymes (type I and type II esterase) with EDLF had no effect on the extent of inhibition (not shown). In contrast, EDLF was completely inactivated by mild heating in air at 150° C and also by heating in 6N HC1 at 110° C for 24 hours. EDLF was unaffected by short-term boiling in water at pH 5.5 (not shown). EDLF was surprisingly susceptible to alkaline hydrolysis; inhibitory activity was lost after incubation in 0.2N NH4OH for 1 hour at 37° C. Based on the results obtained, it appears that EDLF is an organic compound with functional groups susceptible to acid and especially alkaline hydrolysis. The results from the enzyme experiments indicate that functional groups of importance to inhibition are either not connected by ester linkage or that such bonds, if present, are inaccessible to the active site of the enzyme. In addition the insensitivity to proteolytic enzymes clearly suggests that EDLF is not peptidic.
Specificity of Endogenous Digitalislike Factor
One of the notable characteristics of the cardiac glycosides and their aglycones is their specificity as inhibitors of the sodium pump. EDLF in amounts sufficient to fully suppress the red blood cell or dog kidney Na,K-ATPase had no discernible effect on the Ca-ATPase from either rabbit muscle sarcoplasmic reticulum or the human red blood cell membrane (not shown). In addition, the red blood cell Mg-ATPase and guinea pig stomach H,K-ATPase were also insensitive to maximally effective amounts of EDLF. These results indicate that EDLF, like the exogenous digitalis glycosides, is a specific inhibitor of the Na,K-ATPase. Figure 2 shows the effect of EDLF on the uptake of flux as illustrated in Figure 2A . No significant effects of EDLF on the ouabain-insensitive portion of uptake, which reflects the combination of secondary active transport, facilitated exchange, and passive leak, were found ( Figure 2B ). The noticeable time dependency of the inhibition of the ouabainsensitive Rb uptake shown in Figure 2A appeared to follow a simple first-order mechanism as judged from the semilogarithmic plot shown in Figure 2C . These data suggest that the mechanism of inhibition by EDLF of the red blood cell sodium pump involves an interaction with a single class of binding sites.
Action of Endogenous Digitalislike Factor on Uptake of m Rb by Red Blood Cells
Affinity of Endogenous Digitalislike Factor for Sodium-Potassium Adenosine Triphosphate
Of considerable significance to the potential physiological role of EDLF is the intrinsic binding affinity of its receptor. To obtain the dissociation constant and the molarity of EDLF, titration experiments were performed whereby the concentration of Na,K-ATPase was varied in a systematic means in the presence of a fixed (unknown) concentration of EDLF. By performing parallel experiments in the absence of inhibitor, the fraction of enzyme active was determined as a function of the concentration of the Na,K-ATPase. From this data, it was possible to solve for the dissociation constant and the concentration of EDLF as shown in Figure 3 . The derived parameters from the data shown yielded estimates for the concentration of EDLF of 8.5 nM and a dissociation constant of <0.3 nM. By comparison, similar experiments performed with 30 nM ouabain yielded values of 24 nM for the calculated concentration and a dissociation constant of 4.2 nM. This latter figure agrees well with that obtained independently for ouabain by Scatchard analysis (3-7 nM, not shown) and serves to validate the data from the enzyme titration experiments. These results indicate that the human plasma EDLF binds with an apparent affinity greater than 14 times that for ouabain under the conditions used here. Moreover, these data suggest that EDLF may be the most potent inhibitor of the Na,K-ATPase yet described.
Potency of Endogenous Digitalislike Factor in Different Assays
The ability to determine the EDLF concentration by the enzyme titration studies facilitated the generation of dose-response relations for each of three different assay techniques. In these experiments, known concentrations of EDLF were incubated with human red blood cells or dog kidney Na,KATPase for 2 hours under conditions known to promote high-affinity binding of cardiac glycosides (Mg-ATP+Na + ). A second incubation was then performed as follows. Results from this procedure are shown in Figure  4 . All the curves obtained showed Hill coefficients ranging between -0.9 and -1 . 1 , compatible with the interaction of EDLF with a single class of binding sites according to Michaelis Menton kinetics. In each case, the dose-response curves were parallel within experimental error to those obtained It should be noted that each of the apparent K, values obtained from the dose-response curves will slightly overestimate the true value since some small fraction of the bound EDLF or ouabain will dissociate during the second incubation. Overall, the results show that EDLF interacts with the sodium pump at a single class of binding sites with an affinity 10-20 times higher than ouabain.
We also examined the apparent cross-reactivity of EDLF to a commonly used digoxin-specific antibody available from New England Nuclear. EDLF was found to have a cross-reactivity equivalent to 0.0152% that of digoxin (not shown). The very weak cross-reactivity shows that EDLF is not digoxin and indicates that this antibody is not suitable for the quantitation of EDLF. Discussion A novel EDLF has been purified from human plasma and has been shown to possess many of the critical properties of the cardenolides. The EDLF we describe here is an acid-and alkali-labile uncharged polar compound of low molecular weight that appears to be nonpeptidic. EDLF is a highaffinity, specific, and time-dependent inhibitor of the transport, hydrolytic, and receptor functions of the Na,K-ATPase. This report is the first to describe a complete preparative scale purification sequence and characterization of human plasma EDLF. In the present study, we have used the plasma obtained by plasmapheresis of mostly normotensive individuals for the purification of EDLF. Their plasma appears to represent an enriched source of volume-sensitive materials. Substantial evidence supports the existence of a volume-sensitive sodium transport inhibitor.
81012 - 22 The possibility that the factor we describe may be the functional expression of the same entity is supported by the following observations: First, the plasma levels of EDLF increase with acute expansion of extracellular fluid volume in dogs 22 and in sheep, pigs, rats, and humans. 8 Secondly, we have found increased levels of an inhibitor of the sodium pump in the plasma from deoxycorticosterone acetate-hypertensive pigs, which may cochromatograph with the human EDLF (unpublished observations). Third, the pig material shows pseudo-first-order inhibition kinetics similar to those obtained with human EDLF (Figure 2C ). Fourth, partially purified EDLF obtained from the second step of chromatography ( Figure IB) inhibits the ouabain-sensitive uptake of ''Rb by isolated segments of the rat tail artery (unpublished observations); this assay is used extensively to probe for a sodium pump inhibitor after acute and chronic expansion of extracellular fluid volume. 91012 Collectively, these observations support the idea that EDLF and the humoral sodium pump inhibitor described in other studies may be congeneric. Definitive evidence will require structural characterization and an evaluation of the relevant biological properties.
A number of laboratories are involved in the purification of digitalislike factors. Na,K-ATPase inhibitors have been reported in hypothalamic extracts, 23 36 By analogy with the exogenous cardenolides, an EDLF should fulfill a number of functional criteria. These include: 1) selective and reversible inhibition of Na,K-pump activity, 2) a competitive interaction with other cardenolides for binding to the sodium pump, 3) specific inhibition of Na,K-ATPase activity, and 4) high affinity. In addition to these criteria, crossreactivity to antibodies raised against specific cardenolides has also been considered as an important property. 313537 However, many of these antibodies show little cross-reactivity with other closely related cardiac glycosides that are fully functional inhibitors of the Na,K-ATPase. 8 For example, the EDLF we describe shows little cross-reactivity with a commercially useful digoxin antibody.
An important determinant of the physiological role played by EDLF is its concentration in native plasma. Although not definitive, estimates of the probable concentration can be made from analysis of the purification procedure. For example, approximately 0.8 ptg EDLF was obtained at 10% yield (chromatographic steps 2-6) from 125 1 human plasma. Assuming a molecular weight around 340 for EDLF as suggested, 2235 the average concentration in the pooled plasma used for purification may be 180-250 pM. This concentration agrees well with similar estimates (200-320 pM) made for the plasma from volume-expanded dogs. 22 Although the concentration of EDLF in the volume-expanded plasma is roughly one-twentieth that of a digitalizing dose of digoxin, the much higher binding affinity (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) times that for ouabain) of the EDLF suggests that it may be an effective physiological modulator of the sodium pump. In this regard, the acute administration of digoxin to humans and pigs in therapeutic doses results in the inhibition of roughly 20-30% of the available sodium pumps in red blood cells in vivo. At the concentrations of EDLF found in the plasma from volume-expanded individuals, it is possible to predict inhibition of 15-25% of the available sodium pumps. These estimates are similar to those reported during acute or chronic forms of volume expansion and also where low-renin forms of hypertension prevail.
48 -' 3 In summary, we have described a procedure for the routine isolation of EDLF from large volumes of human plasma. The presence of this material in the human circulation, coupled with its high intrinsic affinity and selectivity for the sodium pump, suggests that it may play a role in the modulation of cellular electrolyte homeostasis. The in vivo actions of this factor and its potential vasopressor and natriuretic profiles remain to be explored.
